title: Retinoid x receptor gamma control of affective behaviors involves dopaminergic signaling in mice.
abstract: Abnormal signaling by retinoids or n-3 polyunsaturated fatty acids has been implicated in clinical depression. The converging point in activities of these two classes of molecules is transcriptional activation of retinoid X receptors (Rxr). We show here that ablation of Rxrgamma in mice leads to depressive-like behaviors including increased despair and anhedonia, which were accompanied by reduced expression of dopamine D2 receptor in the shell of nucleus accumbens (NAc) and altered serotonin signaling. While abnormal serotonin signaling is not sufficient to generate the depressive behaviors, increasing D2r expression by chronic fluoxetine (Prozac) treatment or adenoassociated virus type2 (AAV2) mediated expression of Rxrgamma or D2r in the NAc of Rxrgamma(-/-) mice normalizes depressive-like behaviors in Rxrgamma(-/-) animals. Conversely, NAc infusion of raclopride, a D2r antagonist prevents AAV2-Rxrgamma-mediated rescue of despair behaviors in Rxrgamma(-/-) mice. Combined, our data argue that control of NAc D2r expression is critical for Rxrgamma-mediated modulation of affective behaviors.
authors.affiliation: IGBMC (Institut de Génétique et de Biologie Moléculaire et Cellulaire), BP 10142, Inserm, U 596, CNRS, UMR 7104 Illkirch F-67400, France.
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Krzyzosiak
authors.forename: Monika
authors.initials: M
authors.lastname: Szyszka-Niagolov
authors.forename: Marta
authors.initials: M
authors.lastname: Wietrzych
authors.forename: Serge
authors.initials: S
authors.lastname: Gobaille
authors.forename: Shin-ichi
authors.initials: S
authors.lastname: Muramatsu
authors.forename: Wojciech
authors.initials: W
authors.lastname: Krezel
mesh_terms: D000818:Animals; D000928:Antidepressive Agents / Q000627:therapeutic use; D001522:Behavior, Animal / Q000502:physiology; D002452:Cell Count / Q000379:methods; D000229:Dependovirus / Q000502:physiology; D004195:Disease Models, Animal; D004298:Dopamine / Q000235:genetics / Q000378:metabolism*; D018492:Dopamine Antagonists / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005473:Fluoxetine / Q000627:therapeutic use; D005518:Food Preferences / Q000187:drug effects; D005786:Gene Expression Regulation / Q000187:drug effects / Q000235:genetics*; D006220:Haloperidol / Q000494:pharmacology; D046353:Immobility Response, Tonic / Q000502:physiology; D051379:Mice; D018345:Mice, Knockout; D019964:Mood Disorders / Q000188:drug therapy / Q000235:genetics*; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism; D016760:Proto-Oncogene Proteins c-fos / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D018168:Receptors, Retinoic Acid / Q000172:deficiency; D047491:Retinoid X Receptor gamma / Q000172:deficiency / Q000502:physiology*; D012701:Serotonin / Q000378:metabolism; D015398:Signal Transduction / Q000235:genetics*
chemical_list: D000928:Antidepressive Agents; D018492:Dopamine Antagonists; D016760:Proto-Oncogene Proteins c-fos; D012333:RNA, Messenger; D017448:Receptors, Dopamine D2; D018168:Receptors, Retinoic Acid; D047491:Retinoid X Receptor gamma; C082925:retinoic acid receptor beta; D005473:Fluoxetine; D012701:Serotonin; D006220:Haloperidol; D004298:Dopamine